Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research
Eliza Lauer, Jurik Mutter, Florian Scherer
Leukemia (2022) Vol. 36, Iss. 9, pp. 2151-2164
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10
Teresa Calimeri, Nicoletta Anzalone, Maria Giulia Cangi, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 7, pp. e540-e549
Closed Access | Times Cited: 6
Liquid biopsy in cancer current: status, challenges and future prospects
Liwei Ma, Huiling Guo, Yunxiang Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment
Therese Lassen, Torsten Holm Nielsen, Annika von Heymann, et al.
American Journal of Hematology (2025) Vol. 100, Iss. 3, pp. 408-416
Closed Access
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
Mark Roschewski, Dan L. Longo, J. O. Armitage
JAMA Oncology (2025)
Closed Access
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Maciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Blood Advances (2023) Vol. 7, Iss. 14, pp. 3531-3539
Open Access | Times Cited: 15
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Montreh Tavakkoli, Stefan K. Barta
American Journal of Hematology (2023) Vol. 98, Iss. 11, pp. 1791-1805
Open Access | Times Cited: 15
Liquid biopsy in hematological malignancies: current and future applications
Donatella Talotta, Mohammad Almasri, Chiara Cosentino, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas
Sarah Monick, Allison Rosenthal
Cancers (2024) Vol. 16, Iss. 10, pp. 1881-1881
Open Access | Times Cited: 4
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Miaomiao Li, Lan Mi, Chunyang Wang, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Circulating tumor DNA assisting lymphoma genetic feature profiling and identification
Hongbiao Wang, Zhao Wang, Sujuan Zhu, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 4135-4144
Closed Access | Times Cited: 2
Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia
Yu Du, Xiankai Zhang, Ming Sun, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 19
Open Access | Times Cited: 2
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, et al.
Cancer Science (2023) Vol. 114, Iss. 12, pp. 4643-4653
Open Access | Times Cited: 6
Interim FDG-PET/CT for Response Assessment of Lymphoma
Merissa N. Zeman, Esma A. Akin, Reid W. Merryman, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 371-388
Closed Access | Times Cited: 11
Clinical applications of circulating tumor DNA in central nervous system lymphoma
Anna Katharina Foerster, Eliza Lauer, Florian Scherer
Seminars in Hematology (2023) Vol. 60, Iss. 3, pp. 150-156
Closed Access | Times Cited: 5
Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas
Ramón Díez-Feijoo, Marcio Andrade‐Campos, Joan Gibert, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 321-321
Open Access | Times Cited: 1
Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma
Sang Eun Yoon, Hyungwoo Cho, Philipp Berning, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 4171-4181
Closed Access | Times Cited: 1
Effective geriatric management strategies for fatal non-Hodgkin lymphoma: Insights from a case report
Deysi Cristina Páez-Calvopiña, Alberto Bustillos, Elena Vicenta Hernández Navarro, et al.
Medwave (2024) Vol. 24, Iss. 06, pp. e2747-e2747
Open Access | Times Cited: 1
Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice
Cristina López, Pablo Mozas, Armando López‐Guillermo, et al.
Hemato (2022) Vol. 3, Iss. 4, pp. 595-614
Open Access | Times Cited: 9
Primary refractory plasmablastic lymphoma: A precision oncology approach
Hanno M. Witte, Anke Fähnrich, Axel Künstner, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma
Simon Wu, Piers Blombery, David Westerman, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 8, pp. 929-947
Closed Access | Times Cited: 4
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Ákos Nagy, Bence Bátai, Laura Kiss, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 3, pp. 295-313
Open Access | Times Cited: 4
Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study
Z. Haider, Tove Wästerlid, Linn Deleskog Spångberg, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Long‐term outcomes of frontline intensification in primary CNS lymphoma: A real‐world single‐center experience
H. Wang, Ching‐Fen Yang, Chia‐Hsin Lin, et al.
Cancer Medicine (2023) Vol. 12, Iss. 7, pp. 8089-8101
Open Access | Times Cited: 3
Measurable residual disease after CAR T-cell therapy
Nora Chokr, Alexandra Gomez-Arteaga
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 34-41
Closed Access | Times Cited: 2
Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil
Thaís Fischer, Natalia Pin Chuen Zing, Sérgio Costa Fortier, et al.
Hematology Transfusion and Cell Therapy (2023) Vol. 46, Iss. 2, pp. 137-145
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top